Atlanta Vascular Research Foundation (AVRF) Awarded Innovation PEI Pilot and Discovery Fund Grant.
Through the collaboration between UPEI and AVRF, a novel compound has been created resulting in the chemical combination of 2 distinct nutraceuticals. "Ongoing research suggests that this compound may reverse the inactivation of nitric oxide and may function as a powerful intravascular antioxidant. Initial studies show that this compound is about 100 times more potent than the effects of the 2 compounds individually," stated Dr. Tarek Saleh, Chairman and Professor of Biomedical Sciences at UPEI and a co-investigator and recipient of this grant.
"We are very pleased with Innovation PEI's recognition of our research strength by awarding this grant," stated Bobby Khan, MD, Ph.D., Executive Director of AVRF. "This grant will facilitate the continued collaboration between our institutions and the further development of this novel compound." This research came about as a result of a Fulbright Research Chair awarded to Dr. Bobby Khan in 2009, which opened the doors for the collaboration with UPEI.
Atlanta Vascular Research Foundation and its sister company Carmel Biosciences, headquartered in Tucker, Georgia, are clinical stage biopharmaceutical companies focused on discovering, developing and commercializing drugs to benefit patients with chronic vascular and neurological diseases. The company also has a Phase II-IV clinical research facility and is a regional services provider to pharmaceutical and medical device clients in Cardiology, Metabolics, Rheumatology, Dermatology and Gastroenterology.
|Printer friendly Cite/link Email Feedback|
|Comment:||Atlanta Vascular Research Foundation (AVRF) Awarded Innovation PEI Pilot and Discovery Fund Grant.|
|Date:||Jan 27, 2011|
|Previous Article:||Fishbowl Expands Management Team, Celebrates Record Growth, and Unveils New Programs for 2011.|
|Next Article:||WBT Innovation Marketplace Chooses 100 Investor Vetted Deals to Present at WBT2011.|